SEDUCE OCT Study in Coronary Artery rEstenosis:an Optical Coherence Tomography (OCT) Study

Universitaire Ziekenhuizen KU Leuven50 enrolled

Overview

Different healing responses after treatment of bare metal stent restenosis with implantation of an everolimus-eluting Xience V stent (Abbott Vascular) versus use of a paclitaxel-eluting SeQuent Please balloon (BBraun): an optical coherence tomography study. A prospective, single-centre, randomized clinical trial with clinical, angiographic and OCT follow-up at 9 months.

Background: The optimal treatment of bare metal stent restenosis (implantation of a drug-eluting stent, simple balloon dilatation, CABG) is still not defined. The most used option nowadays is the implantation of a drug-eluting stent (DES). However, this procedure implies application of a double metal layer in the vessel wall, which is linked to delayed healing. Furthermore there might be a higher risk of malapposition of both struts of the bare metal and the newly implanted drug-eluting stents. These phenomenon's might give rise to an increased risk of stent thrombosis in this patient population. Recently, drug-eluting balloons (DEB) were proposed as a new treatment strategy for bare metal stent restenosis. The initial results of this technique look promising. Aim: To compare healing processes after treatment of BMS ISR with balloon dilatation using DEB versus implantation of DES. Methods: 50 patients with BMS restenosis (SVG and bifurcation lesions will be excluded) will be randomized into two treatment groups: SeQuent Please drug-eluting balloon dilatation (group I) versus implantation of an everolimus-eluting Xience V stent (group II). At 9 months, a control angiography with OCT pullback of the treated segment is planned.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Restenosis

Interventions

Sequent Please Paclitaxel eluting balloonDEVICE

Sequent Please Paclitaxel eluting balloon

Xience V everolimus eluting stentDEVICE

Xience V everolimus eluting stent

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patient older than 18 years 2. written informed consent available 3. patient eligible for percutaneous coronary intervention 4. patients with a single or multiple re-stenotic lesion(s) in a previously stented area of a coronary artery (irrelevant whether BMS or DES) 5. Target reference vessel diameter measured by QCA: 2-4 mm 6. Target lesion length measured by QCA \< 24 mm 7. Target lesion stenosis measured by QCA: \> 70%- \< 100% 8. Patients willing to provide written informed consent prior to participation and willing and able to participate in all follow-up evaluations. Exclusion Criteria: 1. Left ventricular ejection fraction of \< 30% 2. Impaired renal function (serum creatinine \> 2.0 mg/dl) 3. Target lesion located in bifurcation 4. Previous and/or planned brachytherapy of target vessel 5. Lesion of the left main trunk \> 50%, unprotected 6. Known allergies to antiplatelet, anticoagulation therapy, contrast media, paclitaxel or everolimus 7. Pregnant and/or breast-feeding females or females who intend to become pregnant (pregnancy test required) 8. Patients with a life expectancy of less than one year 9. Patients who intend to have a major surgical intervention within 6 months of enrolment in the study. 10. Patient currently enrolled in other investigational device or drug trial 11. Patient not able or willing to adhere to follow-up visits 12. Patients who previously participated in this study. -

Locations (1)

University Hospitals Leuven

Leuven, Belgium

Outcomes

Primary Outcomes

Stent strut coverage and stent strut apposition(assessed with OCT)

Time frame: 9 months

Secondary Outcomes

Lumen Loss (in-stent) at 9 months In-segment Late Lumen Loss at 9 months Cumulative MACE rate at 9 months Stent thrombosis at all follow-ups Target vessel revascularisation (TVR) at 12 months Device success

Time frame: 9 months, 12 months, yearly until 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.